See more : Poenina Holding AG (PNHO.SW) Income Statement Analysis – Financial Results
Complete financial analysis of Applied Genetic Technologies Corporation (AGTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Applied Genetic Technologies Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MBT Bancshares, Inc. (MBKL) Income Statement Analysis – Financial Results
- Petratherm Limited (PTR.AX) Income Statement Analysis – Financial Results
- Huayi Tencent Entertainment Company Limited (0419.HK) Income Statement Analysis – Financial Results
- Mayfield Group Holdings Limited (MYG.AX) Income Statement Analysis – Financial Results
- Kanoria Chemicals & Industries Limited (KANORICHEM.BO) Income Statement Analysis – Financial Results
Applied Genetic Technologies Corporation (AGTC)
About Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 325.00K | 500.00K | 2.45M | 41.69M | 24.19M | 39.47M | 47.36M | 2.35M | 1.13M | 942.00K | 1.08M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 325.00K | 500.00K | 2.45M | 41.69M | 24.19M | 39.47M | 47.36M | 2.35M | 1.13M | 942.00K | 1.08M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 49.52M | 44.40M | 35.78M | 33.18M | 32.18M | 26.22M | 38.86M | 16.53M | 8.50M | 3.13M | 2.35M |
| General & Administrative | 16.99M | 14.55M | 13.62M | 12.86M | 14.39M | 11.35M | 10.59M | 10.36M | 5.18M | 1.40M | 787.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.99M | 14.55M | 13.62M | 12.86M | 14.39M | 11.35M | 10.59M | 10.36M | 5.18M | 1.40M | 787.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.50M | 58.95M | 49.40M | 46.04M | 46.57M | 37.57M | 49.45M | 26.89M | 13.69M | 4.54M | 3.14M |
| Cost & Expenses | 66.50M | 58.95M | 49.40M | 46.04M | 46.57M | 37.57M | 49.45M | 26.89M | 13.69M | 4.54M | 3.14M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.00K | 0.00 | 0.00 |
| Interest Expense | 2.67M | 1.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 191.00K | 69.00K |
| Depreciation & Amortization | 1.51M | 1.46M | 1.34M | 1.27M | 1.18M | 912.00K | 567.00K | 376.00K | 334.00K | 285.00K | 262.00K |
| EBITDA | -64.76M | -56.97M | -46.94M | -4.35M | -20.05M | 3.72M | -814.00K | -24.53M | -12.56M | -4.51M | -1.59M |
| EBITDA Ratio | -19,925.23% | -11,394.20% | -1,813.05% | -1.58% | -82.91% | 9.42% | -1.72% | -1,017.08% | -1,379.45% | -479.19% | -147.23% |
| Operating Income | -66.27M | -58.45M | -46.94M | -4.35M | -22.38M | 1.90M | -2.09M | -24.53M | -12.56M | -3.59M | -2.06M |
| Operating Income Ratio | -20,390.46% | -11,690.20% | -1,913.66% | -10.43% | -92.55% | 4.82% | -4.41% | -1,042.14% | -1,112.13% | -381.53% | -190.30% |
| Total Other Income/Expenses | -2.58M | -1.39M | 1.18M | 2.46M | 1.18M | 905.00K | 708.00K | 214.00K | -3.35M | -1.40M | 135.00K |
| Income Before Tax | -68.75M | -59.84M | -45.76M | -1.90M | -21.21M | 2.81M | -1.38M | -24.32M | -15.91M | -4.99M | -1.92M |
| Income Before Tax Ratio | -21,153.85% | -11,968.20% | -1,865.55% | -4.55% | -87.69% | 7.11% | -2.92% | -1,033.05% | -1,409.03% | -529.72% | -177.82% |
| Income Tax Expense | 2.67M | -2.11M | 83.00K | 76.00K | 72.00K | 2.40M | 708.00K | 214.00K | -3.35M | -1.21M | 204.00K |
| Net Income | -71.42M | -57.83M | -45.89M | -2.01M | -21.30M | 407.00K | -1.38M | -24.32M | -15.91M | -4.99M | -1.92M |
| Net Income Ratio | -21,976.62% | -11,565.80% | -1,870.85% | -4.81% | -88.07% | 1.03% | -2.92% | -1,033.05% | -1,409.03% | -529.72% | -177.82% |
| EPS | -1.59 | -1.77 | -2.17 | -0.11 | -1.18 | 0.02 | -0.08 | -1.50 | -4.46 | -1.20 | -0.28 |
| EPS Diluted | -1.59 | -1.77 | -2.17 | -0.11 | -1.18 | 0.02 | -0.08 | -1.50 | -4.46 | -1.20 | -0.28 |
| Weighted Avg Shares Out | 45.03M | 32.76M | 21.10M | 18.16M | 18.11M | 18.07M | 17.81M | 16.25M | 3.57M | 4.15M | 6.89M |
| Weighted Avg Shares Out (Dil) | 45.03M | 32.76M | 21.10M | 18.16M | 18.11M | 18.39M | 17.81M | 16.25M | 3.57M | 4.15M | 6.89M |
5 Reddit Penny Stocks Seeing the Most Chatter Friday
InvestorPlace is closing out a busy week of trading with a look at the Reddit penny stocks seeing the most chatter on Friday. The post 5 Reddit Penny Stocks Seeing the Most Chatter Friday appeared first on InvestorPlace.
AGTC Announces Expansion of Manufacturing and Analytics Capabilities to Advance Commercialization of Gene Therapy Product Candidates
- Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility -
5 Reddit Penny Stocks Seeing the Most Chatter Thursday
It's time to take another look at penny stocks that are popular on Reddit as we dive into those getting the most attention on Thursday. The post 5 Reddit Penny Stocks Seeing the Most Chatter Thursday appeared first on InvestorPlace.
Applied Genetic's XLRP Gene Therapy Shows Improved, Durable Response In Retinal Sensitivity
Applied Genetic Technologies Corporation (NASDAQ: AGTC) has announced additional data from the ongoing X-linked retinitis pigmentosa (XLRP) gene therapy Phase 1/2 trial, including 12-month data from Groups 5 & 6 and 24-month data from two of three Group 4 patients. Groups 5 and 6...
AGTC to Host Conference Call on May 6 at 8:00 AM ET to Discuss XLRP Full 12-Month Data from Highest Dose Groups and 24-Month Data from a Subset of Group 4 Patients of its Ongoing Phase 1/2 Clinical Trial
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that...
AGTC Clinical Investigators Provide Encore Presentation of Data from the Company's Ongoing XLRP and Achromatopsia Phase 1/2 Trials
-Company remains on track to present additional 12-month data from the XLRP and achromatopsia clinical trials in the second quarter of 2021-
AGTC Announces Departure of Chief Scientific Officer
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Mark...
AGTC to Participate in Upcoming Virtual Biotech Corporate Access Day and Cell and Gene Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Company...
AGTC to Present at the Gene Therapy Patient Engagement Summit, Held Virtually, March 24, 2021
-AGTC will highlight the value of the patient voice in gene therapy development-
AGTC to Present at Upcoming Investor Conferences
GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management...
Source: https://incomestatements.info
Category: Stock Reports